DAPA-HF
Dapagliflozin and Prevention of Adverse outcomes in Heart Failure
Doente / População Intervenção / Exposição Comparação Desfecho
In 4,744 patients with HFrEF (with or without diabetes), dapagliflozin reduced worsening HF or CV death versus placebo.
N
4744
Desenho
Double-blind RCT, median 18 mo
Desfecho
Worsening HF or CV death
Relevância
1
Resultado16.3 % vs 21.2 % (HR 0.74). Benefit independent of diabetes.
McMurray JJV, et al. N Engl J Med. 2019;381(21):1995-2008. 10.1056/NEJMoa1911303
Discussão e crítica
Defined SGLT2i as a fourth GDMT pillar. EMPEROR-Reduced confirmed class effect. Dapagliflozin/empagliflozin now standard regardless of diabetes status.